# The Cardiovascular Cost of Stopping

By Nora Bissett, Pricing Editor (https://glpwatchdog.org/authors/nora-bissett) | Published: 2026-08-19 | Updated: 2026-10-27

Canonical page: https://glpwatchdog.org/research/the-cardiovascular-cost-of-stopping

> A review argues that weight and blood sugar fluctuation are themselves cardiovascular risk factors, and that these drugs do not stabilize arteries the way statins do. It also says few data exist on hard outcomes after stopping.

## Key points

- Weight and HbA1c fluctuation are themselves risk factors, independent of where values settle.
- These drugs lack anti-atherosclerotic effects, so the benefit may not outlast the drug.
- The review's own words: 'Few data are available regarding hard outcomes in people discontinuing.'
- Reducing rather than stopping has randomized support: rescue therapy 8% / 25% / 67%.

We recently covered what happens to people’s weight after they stop these drugs, and the answer was reassuring: an average of [half a percent regained in a year](https://glpwatchdog.org/research/what-people-actually-do-after-stopping). A review in Nature Reviews Endocrinology raises a different concern. The cardiovascular cost of stopping, it argues, may not show up in a weight number at all.[1] It is a hypothesis, and the review is clear that it is one. What these drugs have been shown to do for the heart while you take them is on our [heart disease page](https://glpwatchdog.org/conditions/heart-disease).

## The argument

It has three parts, and they carry different amounts of evidence.

1. **Fluctuation itself may be harmful.** Weight and HbA1c variability are established risk factors for cardiovascular and microvascular events, independent of where the values settle. A cycle of losing and regaining could be worse than either state held steady.
2. **The benefit may not outlast the drug.** The review notes these medicines lack anti-atherosclerotic and plaque-stabilizing effects, unlike statins, which change arterial structure. If the cardiovascular benefit depends on continued metabolic effect, it stops when the drug does.
3. **Risk may be elevated acutely on withdrawal**, rather than gradually returning to baseline.

Underneath all three sits the plainer point: re-developing obesity and losing glycemic control returns someone to the risk profile they had before, and time spent at higher risk accumulates.

## What is missing, in the review's own words

> Few data are available regarding the incidence of hard outcomes in people discontinuing such drugs.

That sentence governs everything above.[1] Nobody has measured heart attacks, strokes or deaths in a population that stopped these drugs, against a comparable population that continued. The argument is built from mechanism and from what is known about variability in other contexts. That is a legitimate way to raise a question, but not a way to answer one. A second review published in the same period does report an association between stopping within the first year and later coronary artery disease and heart failure. We take that apparent disagreement apart in [stopping as a clinical transition](https://glpwatchdog.org/research/stopping-as-a-clinical-transition); the short answer is that thin observational data can support both statements at once.

> **This matters because of who stops and why.** The commonest reason is cost, and cost is not a choice for most people who face it. An article that presented a mechanistic hypothesis as established risk would frighten people about a decision they often cannot avoid, and it would be wrong on the evidence. If stopping is being forced on you, the useful response is to ask about alternatives, not to absorb a warning nobody has verified.

## How it fits with the empirical picture

The two findings do not conflict. Weight regain after stopping is, on average and in ordinary care, modest, largely because most people do something else afterward.

The cardiovascular question is different and unanswered. It is possible for average weight regain to be small while a subset who lose and regain repeatedly accumulate risk that no average captures. The individual variability noted in the discontinuation data leaves plenty of room for that.

This argument also makes a middle option more attractive: reducing the dose instead of stopping. The randomized evidence for that is covered in [the maintenance trial](https://glpwatchdog.org/research/tirzepatide-maintenance-dose-trial), where rescue therapy was needed by 8% who stayed on full dose, 25% who stepped down, and 67% who stopped.

## What to do with an unanswered question

- **Treat cost as a clinical problem, early.** If affordability is likely to end treatment, that belongs in the conversation before starting, not after stopping.
- **Ask about reducing before stopping.** A lower dose is a real option with randomized support behind it.
- **Avoid the cycle if you can.** Repeated stopping and restarting is the pattern this hypothesis is most concerned about.
- **Do not read this as a reason to panic about a single interruption.** Nothing here establishes that, and the review says as much.

## Frequently asked questions

### Is it dangerous to stop a GLP-1?

Nobody knows. A review raises the concern that weight and blood sugar fluctuation are themselves cardiovascular risk factors and that these drugs, unlike statins, do not change arterial structure, so benefit may stop when the drug does. It also states that few data exist on hard outcomes in people who discontinue.

### Does that contradict the finding that people barely regain weight?

No. Average regain in ordinary care is small, largely because most people do something else afterward. It remains possible for the average to look fine while a subset who repeatedly lose and regain accumulate risk that no average captures.

### Why does fluctuation matter?

Weight and HbA1c variability are established risk factors for cardiovascular and microvascular events independently of where the values settle. That is why a cycle of loss and regain is theorized to be worse than either state held steady.

### Is there an alternative to stopping entirely?

Reducing the dose has randomized evidence behind it. In one trial, rescue therapy was needed by 8% of those who stayed on their full dose, 25% of those stepped down, and 67% of those who stopped. Stepping down did better than stopping and worse than continuing.

### Should I worry if I have to stop for cost reasons?

Not on the strength of this. It is a mechanistic argument, not a measured outcome, and the review says so. The useful response is to ask about lower-cost alternatives or a reduced dose rather than to absorb a warning nobody has verified.

## References

1. Ceriello A, Prattichizzo F, Mastan Sheik Abdullah AR, et al. Causes and consequences of discontinuation of GLP1RAs or tirzepatide. Nature Reviews Endocrinology. 2026. PMID: 42168641. https://pubmed.ncbi.nlm.nih.gov/42168641/

---

Cite as: GLP Watchdog, Nora Bissett, "The Cardiovascular Cost of Stopping", published 2026-08-19, updated 2026-10-27. https://glpwatchdog.org/research/the-cardiovascular-cost-of-stopping

Canonical HTML page: https://glpwatchdog.org/research/the-cardiovascular-cost-of-stopping

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.
